Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Stats
Total: 3 #1
CompanyCogent Communications Holdings, Inc.
IndustryDiversified Communication Services
Market Cap1.32BEPS (ttm)-0.03
P/E-EPS this Y-98.30%
Forward P/E65.49EPS next Y281.90%
PEG-EPS past 5Y15.50%
P/S3.41EPS next 5Y17.00%
P/B58.02EPS Q/Q-33.30%
Dividend4.69%Sales Q/Q4.40%
Insider Own1.00%Inst Own88.80%
Insider Trans-4.93%Inst Trans0.38%
Short Float14.71%EarningsOct 09/b
Analyst Recom2.20Target Price35.07
Avg Volume553.88K52W Range25.84 - 39.11
Oct-05-15 07:37AMQ4 picks for your portfolio: Pro
Oct-01-15 08:52AMCOGENT COMMUNICATIONS HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Stateme
Sep-23-15 08:45AMTop Analyst Upgrades and Downgrades: ADT, CarMax, Cogent, Intel, Monsanto, Noble, Raytheon and Many More at 24/7 Wall St.
Sep-22-15 01:02PMLevel 3 Communications, Cogent Rated Outperform at Investor's Business Daily
Sep-21-15 02:42PMCOGENT COMMUNICATIONS HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Sep-16-15 02:28PMCogent Communications CEO to Present at the Deutsche Bank 23rd Annual Leveraged Finance Conference PR Newswire
Sep-01-15 01:12PMCogent Communications Holdings, Inc. Earnings Q2, 2015
Cogent Communications Holdings, Inc., through its subsidiaries, provides high-speed Internet access and Internet protocol communications services primarily to small and medium-sized businesses, communications service providers, and other bandwidth-intensive organizations in North America, Europe, and Japan. It offers on-net Internet access services to bandwidth-intensive users, such as universities, other Internet service providers, telephone companies, cable television companies, Web hosting companies, content delivery network companies, and commercial content and application service providers; and to corporate customers located in multi-tenant office buildings, including law firms, financial services firms, advertising and marketing firms, and other professional services businesses. The company also provides its on-net services in carrier-neutral co-location facilities, company controlled data centers, and single-tenant office buildings. In addition, it offers off-net services to businesses that are connected to its network primarily by means of last mile' access service lines obtained from other carriers primarily in the form of metropolitan Ethernet circuits. Further, the company provides Internet connectivity to customers that are not located in buildings directly connected to the company's network, as well as offers voice services. Cogent Communications Holdings, Inc. operates 49 data centers. The company was founded in 1999 and is headquartered in Washington, the District of Columbia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KILMER HENRY WVP of IP EngineeringOct 05Sale27.521,00027,52038,000Oct 05 11:19 AM
ONEILL TIMOTHY GVP Field EngineeringOct 01Sale27.231,00027,23040,452Oct 02 09:59 AM
Ortega ErnestChief Revenue OfficerSep 16Sale28.032,20061,66638,800Sep 17 09:29 AM
KILMER HENRY WVP of IP EngineeringSep 03Sale27.281,00027,28039,000Sep 03 02:38 PM
BEURY ROBERT N JRVP & Chief Legal OfficerSep 01Sale27.421,00027,41749,640Sep 01 04:38 PM
CompanyIntelliPharmaCeutics International Inc.
IndustryDrug Delivery
Market Cap42.55MEPS (ttm)-0.23
P/E-EPS this Y70.70%
Forward P/E36.00EPS next Y129.40%
PEG-EPS past 5Y2.20%
P/S8.51EPS next 5Y-
P/B15.00EPS Q/Q-50.00%
Dividend-Sales Q/Q-79.00%
Insider Own0.93%Inst Own0.50%
Insider Trans0.00%Inst Trans-4.83%
Short Float6.43%EarningsOct 09/b
Analyst Recom1.30Target Price9.33
Avg Volume134.41K52W Range1.75 - 3.92
Oct-09-15 07:12AMIntellipharmaceutics reports 3Q loss
Oct-09-15 07:06AM7:06 am Intellipharmaceutics Intl reports Q3 EPS of ($0.08) vs ($0.05) Capital IQ Consensus Estimate; revs -34% y/y to $0.8 mln vs $1.1 mln last year
Oct-09-15 07:00AMIntellipharmaceutics Announces Third Quarter 2015 Results GlobeNewswire
Oct-09-15 07:00AMIntellipharmaceutics to Present at Dawson James Securities Growth Stock Conference GlobeNewswire
Aug-05-15 08:15AMIntellipharmaceutics Updates Status of Tentative Approvals of Generic Focalin XR(R) GlobeNewswire
Intellipharmaceutics International Inc., a pharmaceutical company, engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. The company develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its products under abbreviated new drug application stage include Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorders; Effexor XR, a venlafaxine hydrochloride extended-release capsule for depression; Protonix, a tablet for gastroesophageal reflux diseases; Glucophage XR, a tablet for managing type 2 diabetes; Seroquel XR, a tablet for the treatment of schizophrenia, as well as bipolar and depressive disorders; Lamictal XR, a tablet for anti-convulsant for epilepsy; Keppra XR, a tablet for the treatment of partial onset seizures for epilepsy; and Pristiq, a tablet for depression. The company is also developing Oleptro, a trazodone hydrochloride extended release tablet for treating depression; Coreg CR, a capsule, which is in late-stage development for heart failure and hypertension; OxyContin, a controlled release capsule that is in phase I clinical trial for pain; and Lyrica, a capsule, which is in phase I clinical trial for neuropathic pain. Its non-generic products under development include Rexista, an oral formulation for pain relief; and Regabati XR, a pregabalin extended release capsule that has completed an initial phase I clinical trial for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury, and fibromyalgia. The company has a license and commercialization agreement with Par Pharmaceutical, Inc. Intellipharmaceutics International Inc. is headquartered in Toronto, Canada.
CompanyLeading Brands Inc.
IndustryBeverages - Soft Drinks
Market Cap10.13MEPS (ttm)-0.08
P/E-EPS this Y-71.40%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-19.00%
P/S1.04EPS next 5Y-
P/B1.05EPS Q/Q-320.00%
Dividend-Sales Q/Q-20.70%
Insider Own9.04%Inst Own19.00%
Insider Trans0.00%Inst Trans-
Short Float0.11%EarningsOct 09/b
Analyst Recom2.00Target Price4.40
Avg Volume3.44K52W Range2.83 - 4.27
Oct-09-15 08:30AMLeading Brands, Inc. Announces Q2 Results GlobeNewswire
Jul-10-15 08:30AMLeading Brands, Inc. Announces Q1 Results GlobeNewswire
Leading Brands, Inc., together with its subsidiaries, engages in the development, production, marketing, and distribution of beverages in Canada, the western United States, and Asia. The company is also involved in beverage bottling, as well as the distribution, sale, merchandising, brand development, brand licensing, and brand management of beverage products. Its principal product lines include juices and other premium beverages. The company sells its products under the TrueBlue, PureBlue, TrueBlack, and Happy Water brands. It sells branded and licensed beverage products through its integrated distribution system of distributors, wholesalers, and grocery chains. The company was formerly known as Brio Industries Inc. and changed its name to Leading Brands, Inc. in October 1999. Leading Brands, Inc. was founded in 1986 and is headquartered in Vancouver, Canada.